Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial
David Wimbury, Masahiro Muto, Jasraj S. Bhachu, Katrin Scionti, Jeremy R. Glissen Brown, Karen Molyneux, Claudia Seikrit, Dita Maixnerová, Laura Pérez‐Alós, Peter Garred, Jürgen Floege, Vladimı́r Tesař, Bengt Fellström, Rosanna Coppo, Jonathan Barratt
Abstract
David Wimbury, Masahiro Muto och Bengt Fellström delar förstaförfattarskapet
Topics & Concepts
BudesonideMedicineNephropathyAntibodyImmunologyEndocrinologyAsthmaDiabetes mellitusRenal Diseases and GlomerulopathiesPlatelet Disorders and TreatmentsAmyloidosis: Diagnosis, Treatment, Outcomes